Invesco S&P 500 Equal Weight Health Care ETF (RSPH)
Health care is the broadest of any sector — it spans pharmaceutical giants selling blockbuster drugs worldwide, massive hospital operators and insurers managing millions of patients, device makers from bandages to surgical robots, biotechnology firms chasing the next breakthrough cure, and everything between. The Invesco S&P 500 Equal Weight Health Care ETF (RSPH) holds every one of these companies in the S&P 500, but with a crucial twist: it weighs them equally rather than by size.
This choice matters enormously. In an ordinary, cap-weighted health care fund, the largest pharmaceutical and insurance companies dominate the portfolio because they have the highest stock prices and biggest earnings bases. A fund weighted this way reflects the market’s judgment that companies like Johnson & Johnson and UnitedHealth are the core of the sector. RSPH rejects this. It says all health care companies in the index deserve equal standing, whether they are trillion-dollar pharma behemoths or mid-sized device innovators. The result is a health care fund that tilts toward smaller, more specialized, and often faster-growing companies while diluting the weight of the established megacaps.
The health care sector under equal weight
Health care investing normally means making a bet on two things at once: will the sector outperform the broader market, and which kind of health care company will do better — pharma, devices, insurers, biotech, or services? A cap-weighted health care fund implicitly makes the market’s choice on both questions. RSPG makes the first bet but deliberately muddies the second. By giving equal weight to all types of health care stocks, it captures pharma exposure, device exposure, insurer exposure, and everything else without letting any one type dominate through sheer size.
This approach appeals to investors who believe health care will outperform because of demographic trends — an aging population needs more drugs, more surgeries, more hospital care — but who are unsure which corner of health care will lead. Equal weighting provides a hedge: if insurers falter but device makers soar, the portfolio automatically captures both directions because neither dominates. If biotech has a runaway year, a smaller slice of the portfolio is waiting to participate.
The downside is concentration risk of a different flavor. While RSPH avoids being overweight any single mega-firm, it is overweight a sector — health care — compared to the broader market. And within health care, it tilts toward smaller and mid-sized companies, which are often more volatile and sensitive to changes in regulation, drug approvals, and clinical outcomes than established giants.
Rebalancing and sector rotation
Like all equal-weight funds, RSPH rebalances quarterly. This matters in health care because the sector contains wildly different types of returns. A pharma company might be flat while a biotech firm is soaring, or vice versa. The rebalancing forces the fund to trim whatever has performed best and buy whatever has lagged, locking in a value discipline. Over long periods, this can smooth returns and prevent the portfolio from drifting toward the hottest subsector. But in the short term, it means selling winners and buying losers — a stance that works well in mean-reverting markets and poorly in trend-following ones.
Health care stock prices are often driven by clinical trial results, regulatory approvals, and patent expirations — events that create sharp, non-reversible moves rather than cyclical swings. A drug approval for an Alzheimer’s treatment might send a biotech stock up permanently, and rebalancing RSPH quarterly will not undo that move gradually, it will just trim the winner after the fact. Investors should understand that equal weighting in health care provides systematic value discipline but no ability to time breakthrough moments.
The diversity problem and strength
Health care is unusual because it contains fundamentally different business models. A drug company discovers and manufactures chemicals that treat disease, with very high R&D costs, long development timelines, and often blockbuster upside if a drug succeeds. An insurer collects premiums from employers and individuals and pays out claims, with thin margins and cyclicality tied to unemployment and health trends. A hospital operator runs infrastructure, managing labor and capital intensity. A device maker manufactures specialized equipment with moderate capital intensity and longer product lifespans than drugs.
These businesses behave differently in different economic environments. A recession might crush elective surgeries (bad for device makers and hospitals) while benefiting insurers (who collect premiums and pay out fewer claims because people avoid care). Rising health costs might drive insurer consolidation (good for incumbents) or regulatory crackdowns (bad for everyone). Drug patents expiring hurt pharma but benefit generic makers and insurers. RSPH’s equal weighting means it is constantly reshuffling capital among these disparate bets rather than letting one take over.
This is a strength if you believe health care will do well overall but have no conviction on which subsector will lead. It is a weakness if you have a specific thesis — say, “generic drugs will explode” or “medical devices are about to break out” — that calls for overweighting one piece. RSPH forces you to be diversified even if you do not want to be.
Researching RSPH and its holdings
The fund’s prospectus and holdings list (updated quarterly) show the full breakout of pharma, insurers, devices, and biotech. Investors should review this breakdown to understand how much the fund is really tilting toward their intended bet. The annual expense ratio and turnover figures matter for tax efficiency. A reader comparing RSPH to a cap-weighted health care fund will quickly see the difference: RSPH overweights mid-sized and small-cap health care firms while underweighting the giants. That is the fund’s entire point. The health care sector’s long-term drivers — drug development timelines, insurance consolidation, hospital reimbursement, aging demographics — are worth understanding before investing. RSPH gives exposure to all of them at once, without favoring incumbents, which can be valuable for investors confident in health care’s long-term tailwinds but uncertain about the specific winning subsectors.